Oxford Niaspan Study trial

1) HDL-C <40 mg/dl in the previous 12 months together with either: 2a) carotid atherosclerosis (30% to 70% stenosis identified using carotid ultrasound); 2b) peripheral arterial disease (ankle-brachial pressure index <0.9); or 2c) type 2 diabetes with coronary artery disease (>50% stenosis of major epicardial vessel at angiography). There was no specific LDL-C inclusion criterion, but all patients were already taking statins

Exclusion criteria

contraindications to MRI or to NA (e.g., elevated liver enzymes or known intolerance); severe carotid stenosis (>70%); existing treatment with fibrates, nicorandil, or oral nitrates; recent acute coronary syndrome; uncontrolled diabetes; fasting triglyceride level >500 mg/dl; active peptic ulcer disease; and cardiac failure requiring diuretic treatment

Baseline characteristics

Male (%)	94%
Age (years)	65y
Diabetes (%)	64%

Method and design

Randomized effectives	35 / 36 (studied vs. control)
Design	Parallel groups
Blinding	double blind
Follow-up duration	1 year
Number of centre	single-center
Geographic area	USA
Hypothesis	Superiority
Primary endpoint	carotid artery wall area

Results

No results available for this trial - no clinical endpoint reported

Meta-analysis of all similar trials:

cholesterol lowering intervention in cardiovascular prevention for all chronical situations

HDL increasing drugs in cardiovascular prevention for all type of patients

niacin in cardiovascular prevention for all type of patients

Reference(s)

TrialResults-center ID	TRC10051
Trials register #	NCT00232531

Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I, Digby JE, Bannister T, Handa A, Wiesmann F, Durrington PN, Channon KM, Neubauer S, Choudhury RP. Effects of high-dose modified-release nicotinic Acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study.. J Am Coll Cardiol 2009;54:1787-94
Pubmed | Hubmed | Fulltext